GlassScriptPhysician profile
Rohit Anand
NPI 1902243025
$1,382.83
in general payments reported to CMS, 2019-2025
15 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $329 · 2024: $226 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.08 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.94 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $211.73 | 2023-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $94.80 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $68.95 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $61.68 | 2023 | Idacio |
| Boston Scientific Corporation | $45.68 | 2024 | X-Tack Endoscopic Helix Tacking System, Agile Esophageal |
| Intercept Pharmaceuticals, INC. | $41.47 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.41 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.47 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $29.79 | 2023 | |
| Qol Medical, LLC | $27.59 | 2023 | Sucraid |
| Braintree Laboratories, INC. | $26.18 | 2025 | Sutab, Suflave |
| Pfizer INC. | $23.74 | 2025 | |
| Madrigal Pharmaceuticals | $16.32 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.